HIPEC Treatment for Mesothelioma Patients

HIPEC surgery, also known as heated or hyperthermic intraperitoneal chemotherapy, is the process of heating chemotherapy drugs and delivering them into the abdominal cavity. This treatment is often combined with cytoreductive surgery and is an effective approach for peritoneal mesothelioma.

Watch the Video
Dr. Charles Conway explains the HIPEC treatment for peritoneal mesothelioma patients.

Content Contributors

Scroll

Written By

Edited By

This page features: 11 cited research articles

Cytoreduction and HIPEC surgery is a multimodal treatment plan that has significantly improved survival for peritoneal mesothelioma patients.

The average survival was around six months before this therapy became available. Now half of patients who qualify for HIPEC surgery live longer than five years.

A 2018 International Journal of Hyperthermia study looked at the outcomes for 76 peritoneal mesothelioma patients treated with HIPEC surgery. Median disease-free survival was almost five years, and median overall survival was more than eight years.

Doctors developed the HIPEC procedure to improve the relatively poor results of traditional chemotherapy treatment. Although many patients respond well to unheated chemotherapy drugs, the effects are often short-lived.

Overview of HIPEC Surgery

Although the specific approach to HIPEC surgery can vary depending on the doctor and treatment center, the general concept is always the same. The procedure has two phases: Cytoreductive surgery followed by heated chemotherapy.

Phase I: Surgery

First, doctors perform cytoreductive surgery to remove as much tumor growth as possible from the abdominal cavity.

HIPEC without surgery is ineffective because the chemo drugs cannot penetrate deep into cancerous tumors. In some cases, complete removal of the tumors is impossible and patients may need to explore other treatment options.

HIPEC Machine
Process of HIPEC treatment

Phase II: Chemotherapy Bath

Mesothelioma doctors any remaining cancer cells with heated chemotherapy immediately after surgery to extend survival and prevent cancer recurrence.

The usual chemotherapy drugs, including carboplatin, cisplatin, doxorubicin, gemcitabine and pemetrexed, have all been used for heated chemotherapy. Instead of injecting these drugs into your blood, doctors deliver them directly to the chest or abdomen.

How the HIPEC machine works

  • Doctors insert catheters into the abdominal cavity and connect them to the perfusion system, which heats the chemotherapy solution and pumps it to and from the body.
  • As the solution flows through the machine, a heating element raises it to between 105 and 109 F. Cancer cells start to die when heated to around 104 F, while normal cells can survive up to 111 F.
  • A doctor massages the abdomen by hand to ensure the solution is fully mixed. This step helps the drugs reach remaining cancer cells.
  • The chemotherapy drugs flow between the patient and perfusion system for about one hour.
  • When the chemotherapy bath is finished, doctors drain the medicated solution from the body.
  • The cavity is later rinsed with only a saline solution before the catheter is removed and incision is closed.

The entire procedure, including surgery and HIPEC, may take between six and 18 hours to complete because surgery times vary. The more the cancer has spread within the abdomen, the longer surgery will take.

Recovery

After HIPEC surgery, you should expect a recovery time of several months. Your treatment team will go over everything you need to know about the recovery process, including how to care for your incision wounds and encourage healing.

The most challenging aspect of recovery is fatigue. It will likely take two to three months until you begin to feel back to normal. Until then, it is important to stay active (within your limits) and maintain good nutrition.

Mesothelioma Nutrition Guide

Exclusive Mesothelioma Nutrition Guide

Eating right and balancing your diet while undergoing peritoneal mesothelioma treatment can help ease your symptoms.

Get Free Recipes & Tips

Benefits of HIPEC Surgery

  • Best survival rates of any peritoneal mesothelioma treatment
  • Fewer side effects than traditional chemotherapy
  • Safe delivery of higher drug doses than systemic chemotherapy
  • Local application means more cancerous cells than normal cells are exposed to the drugs, which prevents resistance to chemotherapy

Side Effects of HIPEC Surgery

  • Bleeding
  • Wound infections
  • Urinary tract infections
  • Blood clots
  • Pneumonia
  • Bowel obstruction
  • Disruption of normal bowel motility (which reduces appetite)
  • Fistula (a connection between the skin and intestines)
  • Myelosuppression (bone marrow produces fewer platelets and blood cells)
  • Sepsis

Which Patients Are Eligible for HIPEC Treatment?

As with any aggressive treatment, not all patients are eligible for HIPEC treatment.

Peritoneal mesothelioma patients must:

  • Be healthy enough for surgery
  • Not have heart disease or other serious chronic conditions
  • Not have more than one bowel obstruction or partial obstruction
  • Have a low peritoneal cancer index score (which estimates tumor growth and tumor spread)
  • Have an epithelial cell type (other cell types are carefully considered)

Doctors look for patients who are otherwise healthy except for their cancer diagnosis. They conduct assessments to determine a patient’s overall health, which they call performance status.

Get Help Finding a Peritoneal Mesothelioma Doctor

Connect with a top mesothelioma doctor who has the knowledge and experience treating this rare disease.

Get Help Now

Treatment Centers Offering the HIPEC Procedure

The main reason this procedure is not offered as a standard treatment option at all mesothelioma cancer centers is because of the complexity of cytoreductive surgery and lack of familiarity with the HIPEC procedure and equipment.

Studies Show HIPEC Surgery Improves Survival

Numerous studies show HIPEC surgery drastically improves life expectancy in about half of the peritoneal mesothelioma patients who undergo the procedure.

Dr. Paul Sugarbaker’s Study

In 2018, Dr. Paul Sugarbaker, who helped pioneer HIPEC surgery, published an update on the best treatment approaches for peritoneal mesothelioma. His report included survival results from a study he authored in 2017.

Sugarbaker’s study used cytoreductive surgery and HIPEC to treat peritoneal mesothelioma, with some patients also receiving one or two additional types of chemotherapy. Some patients received early postoperative intraperitoneal chemotherapy, commonly called EPIC. Other patients received EPIC plus adjuvant normothermic intraperitoneal chemotherapy, also called NIPEC, which is used long-term to prevent recurrence.

The five-year survival rates included:

  • 44 percent for patients treated with cytoreduction and HIPEC
  • 52 percent for patients who additionally received EPIC
  • 75 percent for patients who additionally received EPIC and NIPEC

Sugarbaker’s results indicate that long-term, nonheated intraperitoneal chemotherapy is an effective maintenance therapy that improves peritoneal mesothelioma survival.

Washington Cancer Institute Study

In 2015, researchers from the Washington Cancer Institute’s Program in Peritoneal Surface Malignancy published results from a study on the survival outcomes of using HIPEC surgery a second time to treat recurrence.

Survival after a second HIPEC surgery was 4.5 years compared to 6.4 years after the first HIPEC surgery. These results suggest the HIPEC procedure is an effective second-line therapy for recurrent peritoneal mesothelioma.

Multicenter Study

In 2009, one of the largest multicenter studies on HIPEC for peritoneal mesothelioma patients published its findings. Dr. Tristan Yan and colleagues confirmed the treatment can significantly extend survival for select patients.

After follow-up with more than 400 patients, the researchers reported an overall median survival of 53 months — nearly 4.5 years. One patient survived for more than 19 years after the procedure.

Survival rates of one, three and five years were 81 percent, 60 percent and 47 percent, respectively.

Future Studies Will Aim to Improve Technique

For the right patients, HIPEC surgery can extend survival and provide a better quality of life.

However, the medical community has yet to reach an agreement on the best drug combination, chemotherapy temperature and exposure time for mesothelioma patients. As researchers uncover more about the technique, it is likely that survival outcomes will continue to improve.

Get the Best Treatment Options

Find a Doctor
Asbestos.com Mesothelioma Packet

Order Your Free Treatment Guide

Get Yours Now

Find a Mesothelioma Clinical Trial Near You

Get Help Now

Registered Nurse and Patient Advocate

Karen Selby joined Asbestos.com in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the regional director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections. She is also a member of the Academy of Oncology Nurse & Patient Navigators.

Walter Pacheco, Managing Editor at Asbestos.com
Edited by
Dr. W. Charles Conway
Medical Review By

17 Cited Article Sources

  1. Gilani, S.N.S. et al. (2018) Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. : 
    Retrieved from: https://www.tandfonline.com/doi/full/10.1080/02656736.2018.1434902
  2. Sugarbaker, P.H. (2018). Update on the management of malignant peritoneal mesothelioma.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204413/
  3. Kalff, J.C. et al. (2017, July 17). Postoperative ileus.
    Retrieved from: https://www.uptodate.com/contents/postoperative-ileus
  4. Kim, J., Bhagwandin, S. & Labow, D.M. (2017). Malignant peritoneal mesothelioma: A review.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497105/
  5. Sugarbaker, P.H. & Chang, D. (2017). Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
    Retrieved from: https://www.sciencedirect.com/science/article/pii/S0748798317300598
  6. Goodman, M.D. et al. (2016). Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754301/
  7. Ihemelandu, C., Bijelic, L., & Sugarbaker, P.H. (2015). Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/25120250
  8. Shetty, S. et al. (2014, April). Comparison of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Mitomycin or Carboplatin for Diffuse Malignant Peritoneal Mesothelioma. The American Surgeon, Volume 80, Number 4, : : 
    Retrieved from: http://www.ingentaconnect.com/content/sesc/tas/2014/00000080/00000004/art00015
  9. Baratti, D. et al. (2013, October). Diffuse Malignant Peritoneal Mesothelioma: Long-term Survival with Complete Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). ScienceDirect. : 
    Retrieved from: http://www.sciencedirect.com/science/article/pii/S0959804913004358
  10. Goodman, M. (2013, August 15). Martin Goodman, MD HIPEC Procedure. Tufts Medical Center. : 
    Retrieved from: https://www.youtube.com/watch?feature=player_embedded&v=3EG_Ac28Bxs
  11. Tannapfel, A. (Ed.). (2011). Malignant Mesothelioma. New York, NY: Springer.
  12. Yan, T., Cao, C. and Munkholm-Larsen, S. (2010, February 15). A Pharmacological Review on Intraperitoneal Chemotherapy for Peritoneal Malignancy. World Journal of Gastrointestinal Oncology. : 
    Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999163/?tool=pmcentrez
  13. Yan, T. et al. (2009, December 20). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. : 
    Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/19917862
  14. Sugarbaker, P., Welch, L., Mohamed, F. and Glehen, O. (2003, July). A Review of Peritoneal Mesothelioma at the Washington Cancer Institute. Surgical Oncology Clinics of North America. : 
    Retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/14567020

  15. Gilani, S.N.S. et al. (2018) Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. : 
    Retrieved from: https://www.tandfonline.com/doi/full/10.1080/02656736.2018.1434902
  16. Sugarbaker, P.H. (2018). Update on the management of malignant peritoneal mesothelioma. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204413/
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

On This Page

Back to Top

Share this article

Last Modified April 15, 2019

Chat live with a patient advocate now